Evidence map›Paper›PMID 25012910›Full record

ArticleMetabolism: clinical and experimental2014

Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study.

Barry I Hudson, Chuanhui Dong, Hannah Gardener, Mitchell S V Elkind, Clinton B Wright, Ron Goldberg, Ralph L Sacco, Tatjana Rundek

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. A Role for Advanced Glycation End Products in Molecular Ageing.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Advanced glycation end products and risk of hypertension in Iranian adults: Tehran lipid and glucose study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Barry I HudsonDivision of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address: bhudson@med.miami.edu.
Chuanhui DongDepartment of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Hannah GardenerDepartment of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Mitchell S V ElkindStroke Division, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman Public School of Health, Columbia University, New York, NY, USA.
Clinton B WrightDepartment of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Neuroscience Program, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Ron GoldbergDivision of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Ralph L SaccoDepartment of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Tatjana RundekDepartment of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
University of Miami · USColumbia University · US

Funding

Stroke Incidence and Risk Factors in a Tri-Ethnic RegionR37NS029993 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ELKIND, MITCHELL S, SACCO, RALPH L. · 2008 to 2014
$12.1M
Genetics Determinants of Extreme Phenotypes of Subclinical AtherosclerosisK24NS062737 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RUNDEK, TATJANA · 2009 to 2013
$975k
NINDS NIH HHS K24 NS062737NINDS NIH HHS R37 NS029993
6 · The paper itself

Abstract

objectiveRecent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. MATERIALS/

methodsFrom the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function.

resultsThe median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p<0.0001), blood pressure (p=0.0014), and fasting glucose (p<0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks.

conclusionssRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.

Indexed as

Down-RegulationAgedBiomarkersBlack or African AmericanBody Mass IndexCohort StudiesCross-Sectional StudiesFemaleHispanic or LatinoHumansHyperglycemiaHypertensionMaleMetabolic SyndromeNew York CityObesity, AbdominalBiomarkersReceptor for Advanced Glycation End ProductsReceptors, ImmunologicBiomarkerCardiovascular diseaseDiabetesMetabolic syndromeRAGE

Identifiers

PMID25012910
PMCPMC4380275
OpenAlexW1970222345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.